Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ArcticZymes Technologies ASA (DE:B4V)
FRANKFURT:B4V
RESEARCH TOOLSreports
Holding DE:B4V?
Track your performance easily
B4V Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.38 - €3.74
Previous Close€1.46
Volume0.00
Average Volume (3M)1.17K
Market Cap
€81.46M
Enterprise Value€62.49M
Total Cash (Recent Filing)kr238.60M
Total Debt (Recent Filing)kr14.87M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Nov 06, 2024EPS Estimate
<€0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume125
30 Day Avg. Volume1,171
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)13.23
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ArcticZymes Technologies ASA News
PremiumCompany Announcements
ArcticZymes Showcases Growth and Innovation at Healthcare Conference
PremiumCompany Announcements
ArcticZymes Innovates Viral Vector Manufacturing
PremiumCompany Announcements
ArcticZymes Unveils Groundbreaking RNA Enzyme
PremiumCompany Announcements
ArcticZymes Reports Q2 Revenue Dip, Eyes GrowthPremiumCompany Announcements
ArcticZymes Technologies Announces Upcoming Financial Presentation
PremiumCompany Announcements
ArcticZymes Technologies Announces Capital IncreasePremiumCompany Announcements
ArcticZymes Expands Capital with New Shares IssuanceOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.13% Mutual Funds
0.01% Other Institutional Investors
99.85% Public Companies and
Individual Investors
B4V FAQ
What was ArcticZymes Technologies ASA’s price range in the past 12 months?
ArcticZymes Technologies ASA lowest stock price was €1.38 and its highest was €3.74 in the past 12 months.
What is ArcticZymes Technologies ASA’s market cap?
Currently, no data Available
When is ArcticZymes Technologies ASA’s upcoming earnings report date?
ArcticZymes Technologies ASA’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were ArcticZymes Technologies ASA’s earnings last quarter?
ArcticZymes Technologies ASA released its earnings results on Aug 22, 2024. The company reported €0.004 earnings per share for the quarter, missing the consensus estimate of €0.012 by -€0.008.
Is ArcticZymes Technologies ASA overvalued?
According to Wall Street analysts ArcticZymes Technologies ASA’s price is currently Overvalued.
Does ArcticZymes Technologies ASA pay dividends?
ArcticZymes Technologies ASA does not currently pay dividends.
What is ArcticZymes Technologies ASA’s EPS estimate?
ArcticZymes Technologies ASA’s EPS estimate is <€0.01.
How many shares outstanding does ArcticZymes Technologies ASA have?
ArcticZymes Technologies ASA has 51,071,390 shares outstanding.
What happened to ArcticZymes Technologies ASA’s price movement after its last earnings report?
ArcticZymes Technologies ASA reported an EPS of €0.004 in its last earnings report, missing expectations of €0.012. Following the earnings report the stock price went down -3.39%.
Which hedge fund is a major shareholder of ArcticZymes Technologies ASA?
Currently, no hedge funds are holding shares in DE:B4V
---
ArcticZymes Technologies ASA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
ArcticZymes Technologies ASA
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments that are Enzymes and Beta-glucans. The company's geographical segments are Norway, Europe, America, Asia/Australia/Africa, out of which Europe accounts for the majority of the revenue.
---
Technical Analysis
---